Lupin Gets Nod For Blood Pressure Drug From USFDA
Indian pharma major Lupin on Wednesday said that it has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Metoprolol Succinate Extended-Release Tablets USP, 25 mg, 50 mg, 100 mg, and 200 mg, to market a generic equivalent of Toprol-XL Tablets of Sequel Therapeutics, LLC.
Metoprolol Succinate Extended-Release Tablets are indicated for high blood pressure and heart failure. The drug can also be used to prevent chest pain (angina). The drug works by lowering blood pressure and heart rate, making it easier for the heart to pump blood to the rest of the body.
This product will be manufactured at Lupin’s Pithampur facility in India. Metoprolol Succinate Extended-Release Tablets USP (RLD Toprol-XL) had estimated annual sales of USD 305 million in the U.S. (IQVIA MAT June 2023).
On Wednesday the company's stock closed 2.89 per cent higher at Rs 1112.95 on BSE.
